Honey bee as apitoxin, carries several active components, the most abundant of which is melittin, and the most biologically active are enzymes, particularly phospholipase A2. Bee venom is under laboratory and clinical research for its potential properties and uses in reducing risks for adverse events from bee venom therapy, rheumatoid arthritis, and use as an immunotherapy for protection against allergies from insect stings. Bee venom products are marketed in many countries, but, as of 2018, there are no approved clinical uses for these products which carry various warnings for potential allergic reactions. With an increased number of honey bees in a specific
Evolution of snake venom model described above, in which genes in other body tissues are duplicated and then recruited to the venom gland before natural selection for toxicity. However, in 2014 a new model was proposed in which salivary protein genes are duplicated and then restricted to the venom gland. This model does away with the recruitment hypothesis and cites the homology between certain venom and body genes as unrelated in the linear fashion described in the traditional birth-and-death model. Gene duplication is not the only way that venom has become more diverse. There have been instances of new venom proteins generated by alternative